Sodium –glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction

ConclusionsTreatment with SGLT2i influenced skeletal muscle pathology in patients with HFrEF and was associated with anti-atrophic, anti-inflammatory, and pro-metabolic effects. These changes may be regulatedvia IL-6 –kynurenine signalling. Together, clinical improvements following SGLT2i treatment in patients with HFrEF may be partly explained by their positive effects on skeletal muscle pathology.

https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3192?af=R

Source: European Journal of Heart Failure - March 12, 2024 Category: Cardiology Authors: Nathanael Wood, Sam Straw, Chew W. Cheng, Yu Hirata, Marcelo G. Pereira, Harrison Gallagher, Stuart Egginton, Wataru Ogawa, Stephen B. Wheatcroft, Klaus K. Witte, Lee D. Roberts, T. Scott Bowen Tags: Research Article Source Type: research